All In MedTech

FDA Clearance Tracker · P950021-S013

ADVIA CENTAUR PSA ASSAY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 15, 2012 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 15, 2012

Approved

Time to decision

203 days

Received Mar 26, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P950021-S013
Device name
ADVIA CENTAUR PSA ASSAY
Applicant location
East Walpole, MA
Received
Mar 26, 2012
Decided
Oct 15, 2012
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P950021

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE LOCATED AT STRATEC BIOMEDICAL SWITZERLAND AG IN BERINGEN, SWITZERLAND.

Source documents

Other decisions for Siemens Healthcare Diagnostics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.